Souhaitez-vous accéder aux communiqués récents ?

Rockville, MD, Aug. 11, 2024 (GLOBE NEWSWIRE) -- In its recently updated industry report, Fact.MR reveals that the global automotive clear vision system market is projected to reach a size of US$...

Dublin, Aug. 08, 2024 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration Market Forecast Report by Disease Type Product Distribution Channel Countries and Company Analysis, 2024-2032" report...

Ottawa, Aug. 02, 2024 (GLOBE NEWSWIRE) -- The global video games market size is predicted to increase from USD 248.52 billion in 2023 to approximately USD 664.96 billion by 2033, According to...

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal...

Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)Safety data were...

More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpointPeople treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80%...

SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...

The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections that...

Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindnessDesigned to simplify administration, Vabysmo PFS...

Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to...